References

1. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol. 2008; 26(12):2013-2019. PubMed | Google Scholar


2. Daniel A. Goldstein, Qiushi Chen, Turgay Ayer, David H. Howard,Joseph Lipscomb, Bassel F. El- Rayes and Christopher R. Flowers. First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States-Based Cost-Effectiveness Analysis.J Clin Oncol.2015 Feb 17. PubMed | Google Scholar


3. Agence nationale de l'assurance maladie. http://www.anam.ma/anam.php?titre_medicament=AVASTIN&id_medicament=AVASTIN&imageField.x=7&imageField.y=7&AjoutMod=oui&ir=1&id_espace=6&id_srub=19.Page consultée le 17 mars 2015. Google Scholar


4. Banque mondiale. http://donnees.banquemondiale.org/indicateur/NY.GDP.PCAP.CD.Page consultée le 17 mars 2015. Google Scholar


5. Luis Prieto , José A Sacristán. Problems and solutions in calculating quality-adjusted life years (QALYs). Health and Quality of Life Outcomes .2003;1:80. PubMed | Google Scholar